Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H
Ann Hematol. 2024; 104(1):841-845.
PMID: 39738826
DOI: 10.1007/s00277-024-06150-8.
Nogueira D, Lage L, Reichert C, Culler H, de Freitas F, Mendes J
Cancers (Basel). 2024; 16(23).
PMID: 39682103
PMC: 11640734.
DOI: 10.3390/cancers16233914.
Olejarz W, Sadowski K, Szulczyk D, Basak G
Int J Mol Sci. 2024; 25(14).
PMID: 39062986
PMC: 11276786.
DOI: 10.3390/ijms25147743.
Florindez J, Chihara D, Reis I, Lossos I, Alderuccio J
Blood Adv. 2024; 8(16):4423-4432.
PMID: 38954843
PMC: 11375286.
DOI: 10.1182/bloodadvances.2024013499.
Zheng W, Liu M, Guan L, Wang S
Cancer Med. 2024; 13(8):e7120.
PMID: 38629251
PMC: 11022146.
DOI: 10.1002/cam4.7120.
High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
Dhar S, Chakravarti M, Ganguly N, Saha A, Dasgupta S, Bera S
Front Immunol. 2024; 14:1303959.
PMID: 38304256
PMC: 10831358.
DOI: 10.3389/fimmu.2023.1303959.
Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression.
Leeman-Neill R, Song D, Bizarro J, Wacheul L, Rothschild G, Singh S
Nat Genet. 2023; 55(12):2160-2174.
PMID: 38049665
PMC: 10703697.
DOI: 10.1038/s41588-023-01561-1.
Investigating and modeling positron emission tomography factors associated with large cell transformation from low-grade lymphomas.
Obeid J, Hiniker S, Schroers-Martin J, Guo H, No H, Moding E
EJHaem. 2023; 4(1):90-99.
PMID: 36819184
PMC: 9928791.
DOI: 10.1002/jha2.615.
Rare Case of Hodgkin Lymphoma Transformation into Diffuse Large B-Cell Lymphoma with Atypical Spread Epidurally, Intradurally and Intramedullary: A Case Report.
Balodis A, Pimenova A, Nikulshin S, Balode G, Hasnere S
Am J Case Rep. 2022; 23:e935014.
PMID: 35213529
PMC: 8886512.
DOI: 10.12659/AJCR.935014.
Follicular lymphoma and macrophages: impact of approved and novel therapies.
Gouni S, Marques-Piubelli M, Strati P
Blood Adv. 2021; 5(20):4303-4312.
PMID: 34570196
PMC: 8945644.
DOI: 10.1182/bloodadvances.2021005722.
Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.
Desai S, Chaturvedi M, Hameed R, Baez-Sosa V, Shenoy A
Oncologist. 2021; 26(9):e1660-e1663.
PMID: 34097758
PMC: 8417860.
DOI: 10.1002/onco.13846.
is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma.
Sun J, Zhu X, Zhao Y, Zhou Q, Qi R, Liu H
Pharmgenomics Pers Med. 2021; 14:397-408.
PMID: 33833551
PMC: 8021264.
DOI: 10.2147/PGPM.S301718.
The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
Nozaki K, Maruyama D, Maeshima A, Tajima K, Itami J, Shichijo T
Eur J Haematol. 2020; 106(2):213-220.
PMID: 33098704
PMC: 7894292.
DOI: 10.1111/ejh.13539.
Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma.
Shichijo T, Maruyama D, Yamauchi N, Maeshima A, Sugano M, Yuda S
Cancer Med. 2020; 9(23):8864-8874.
PMID: 33022120
PMC: 7724492.
DOI: 10.1002/cam4.3501.
Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
Nagy A, Batai B, Balogh A, Illes S, Mikala G, Nagy N
Genes (Basel). 2020; 11(7).
PMID: 32668764
PMC: 7397208.
DOI: 10.3390/genes11070785.
B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.
Gemenetzi K, Agathangelidis A, Zaragoza-Infante L, Sofou E, Papaioannou M, Chatzidimitriou A
Front Oncol. 2020; 10:67.
PMID: 32083012
PMC: 7006488.
DOI: 10.3389/fonc.2020.00067.
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.
Batlevi C, Sha F, Alperovich A, Ni A, Smith K, Ying Z
Eur J Cancer. 2020; 126:78-90.
PMID: 31927165
PMC: 7331469.
DOI: 10.1016/j.ejca.2019.12.006.
Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation.
Yang G, Mills M, Kim Y, Figura N, Doyle C, Oliver D
Blood Cancer J. 2020; 9(12):104.
PMID: 31894139
PMC: 6938796.
DOI: 10.1038/s41408-019-0269-6.
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Mensah F, Blaize J, Bryan L
Onco Targets Ther. 2018; 11:4817-4827.
PMID: 30147333
PMC: 6097514.
DOI: 10.2147/OTT.S142264.
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
Madsen C, Clausen M, Plesner T, Pasanen A, Kuismanen T, Bentzen H
Blood Adv. 2018; 2(13):1562-1571.
PMID: 29976619
PMC: 6039650.
DOI: 10.1182/bloodadvances.2018017673.